trending Market Intelligence /marketintelligence/en/news-insights/trending/qF_GeVOpvAF_5YPoEFosUQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

China approves 1st domestic HPV vaccine

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

China approves 1st domestic HPV vaccine

Chinese regulators approved the country's first domestic human papillomavirus vaccine, according to a notice by the National Medical Products Administration.

The vaccine, Cecolin, is developed by private company Xiamen Innovax Biotech Co. Ltd. and Xiamen University, both based in southeast China's Fujian province.

Human papillomavirus, or HPV, is a group of more than 200 viruses among which about a dozen can cause cancers including vaginal cancer and cervical cancer.

Cecolin is now approved to help prevent females aged between 9 and 45 years old from infections with HPV types 16 and 18. The two viruses cause about 70% of cervical cancers, according to the National Cancer Institute.

There are three HPV vaccines available worldwide — GlaxoSmithKline PLC's Cervarix and Merck & Co. Inc.'s Gardasil 4 and Gardasil 9. Cervarix targets the same two viruses as Cecolin, while Gardasil 4 can prevent infection with four viruses and Gardasil 9 with nine.

Xiamen Innovax also has an HPV vaccine that targets nine viruses. That vaccine is under phase 2 study, according to the company's website.

Xiamen Innovax, established in 2005, also developed the hepatitis E vaccine Hecolin.